Qianhong Pharmaceutical (002550): Heparin API gross margin rebounded, boosting performance and looking forward to innovation, transformation and implementation
Qianhong Pharmaceutical (002550): 2023 performance under pressure 2024Q1 gross margin increased significantly
Qianhong Pharmaceutical (002550) Company Brief Review Report: Heparin APIs are expected to rebound, and innovative research and development are progressing smoothly
Comments on the 2023 Annual Report and 2024 Quarterly Report of Qianhong Pharmaceutical (002550): Cash flow conditions have greatly improved, innovation and transformation can be expected in the future
Qianhong Pharmaceutical (002550): Deepening the innovative layout of the entire heparin industry chain can be expected in the future
Qianhong Pharmaceutical (002550): Deepening the heparin industry chain with excellent results in innovative research and development
Qianhong Pharmaceutical (002550): Stock buybacks show confidence in development, heparin's upward cycle is expected to begin
Qianhong Pharmaceutical (002550): Continued improvement in the heparin supply and demand pattern is expected to start a new cycle of rapid growth
Qianhong Pharmaceutical (002550): Leading heparin API companies layout high-quality upstream resources can be expected in the future
Qianhong Pharmaceutical (002550): Heparin cycle, demolition compensation, exchange profit and loss affect performance layout Qianmu builds core competitiveness
Qianhong Pharmaceutical (002550) Annual Report Review: 2019 Main Business Performance Was Brilliant, 2020 Q1 Was Clearly Impacted by the COVID-19 Pandemic
Qianhong Pharmaceutical (002550) Case Review: The company's main business performance is outstanding and the innovative drug pipeline continues to be rich
Qianhong Pharmaceutical (002550): The ZHB202 clinical trial was approved and development has entered the harvest period
Qianhong Pharmaceutical (002550) Case Review: Innovative drug research and development has welcomed another significant progress since 2019 and has entered a period of harvesting results
Qianhong Pharmaceutical (002550): Employees have consistent shareholding interests and are optimistic about long-term development
Qianhong Pharmaceutical (002550): Continued release of new products and performance is expected to accelerate
Comments on Qianhong Pharmaceutical (002550) semi-annual report: half-yearly report results gratifying company's steady expansion
Qianhong Pharmaceutical (002550): steady income growth performance is expected to improve
Qianhong Pharmaceutical (002550): the performance is basically in line with the expected high-speed release of low molecular weight heparin preparation.
Qianhong Pharmaceutical (002550): Natroheparin was successfully approved to enhance comprehensive competitiveness
No Data